Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Study of 177Lu-CTR-FAPI-targeted Nuclear Drugs in Advanced Metastatic Digestive Malignancies

NCT07014254 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT07014254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07014254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Study of 177Lu-CTR-FAPI-targeted Nuclear Drugs in Advanced Metastatic Digestive Malignancies
Lead sponsor
Xijing Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 20, 2025
Completion date
April 30, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the stomach, colorectal cancer metastatic, neuroendocrine tumor (net), pancreatic ductal adenocarcinoma (pdac)